AlphaHelix Molecular Diagnostics AB Share Price

Equities

ALPH

SE0000885501

Advanced Medical Equipment & Technology

End-of-day quote NORDIC GROWTH MARKET 23:00:00 01/05/2024 BST 5-day change 1st Jan Change
0.314 SEK +2.61% Intraday chart for AlphaHelix Molecular Diagnostics AB -9.25% -23.04%

Financials

Sales 2022 34.33M 3.17M 253M Sales 2023 26.1M 2.41M 192M Capitalization 25.87M 2.39M 191M
Net income 2022 -2M -185K -14.75M Net income 2023 -9M -832K -66.35M EV / Sales 2022 1.17 x
Net cash position 2022 7.24M 670K 53.38M Net cash position 2023 2.52M 233K 18.6M EV / Sales 2023 0.89 x
P/E ratio 2022
-18.7 x
P/E ratio 2023
-2.72 x
Employees 13
Yield 2022 *
-
Yield 2023
-
Free-Float 82.5%
More Fundamentals * Assessed data
Dynamic Chart
AlphaHelix Molecular Diagnostics AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
AlphaHelix Molecular Diagnostics AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
AlphaHelix Molecular Diagnostics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
AlphaHelix Molecular Diagnostics AB Reports Earnings Results for the Third Quarter Ended September 30, 2023 CI
AlphaHelix Molecular Diagnostics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
AlphaHelix Molecular Diagnostics AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
AlphaHelix Molecular Diagnostics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022 CI
AlphaHelix Molecular Diagnostics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
AlphaHelix Molecular Diagnostics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
AlphaHelix Molecular Diagnostics AB Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
AlphaHelix Molecular Diagnostics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021 CI
Alphahelix Molecular Diagnostics AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Alphahelix Molecular Diagnostics AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Alphahelix Molecular Diagnostics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2020 CI
Xanadu Technologies AB, Tataa Biocenter AB and Active Healthtech Nordic AB acquired a 13.17% stake in AlphaHelix Molecular Diagnostics AB from Labkompaniet AB. CI
More news
1 day+2.61%
1 week-9.25%
Current month+2.61%
1 month+19.85%
3 months-25.94%
6 months-42.49%
Current year-23.04%
More quotes
1 week
0.12
Extreme 0.12
0.32
1 month
0.12
Extreme 0.12
0.35
Current year
0.12
Extreme 0.12
0.50
1 year
0.12
Extreme 0.12
0.79
3 years
0.12
Extreme 0.12
3.57
5 years
0.12
Extreme 0.12
3.57
10 years
0.12
Extreme 0.12
3.57
More quotes
Managers TitleAgeSince
Chairman 55 -
Director/Board Member 68 28/02/11
Members of the board TitleAgeSince
Director/Board Member 68 28/02/11
Chairman 55 -
Director/Board Member 57 -
More insiders
Date Price Change Volume
02/05/24 0.314 +2.61% 133,746
30/04/24 0.306 -4.38% 16,758
29/04/24 0.32 +1.27% 41,364
26/04/24 0.316 -8.67% 28,780

End-of-day quote NORDIC GROWTH MARKET, May 01, 2024

More quotes
Alphahelix Molecular Diagnostics publ AB is a Sweden-based company engaged in the development, manufacture and marketing of technology and products for the identification and quantitation of deoxyribonucleic acid (DNA) in molecular diagnostics and life science research. Its product portfolio utilizes polymerase chain reaction (PCR) and is based on the SuperConvection technology, which speeds up thermal cycling and increases temperature homogenization. The Company’s primary product portfolio includes Alpha Amp, a thermal cycler utilizing SuperConvention technology; Alpha Bot, a pipetting robot focused on the automatic set of PCR reactions for the research and clinical activities. The Company’s products can be utilized with DNA analysis in the fields of veterinary diagnostics, forensic DNA analysis, food pathogen detection and biosafety analyses.
More about the company